Thursday, November 17, 2016

BRIEF-Keryx Biopharmaceuticals says most patients treated with ferric citrate achieved main goal in phase 3 trial

* Keryx Biopharmaceuticals announces multiple scientific

presentations of phase 3 trial results of ferric citrate for

iron deficiency anemia (IDA) in non-dialysis dependent chronic

kidney disease...

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)